RE:RE:RE:RE:RE:RE:RE:RE:Short selling could very well be the reason for 30% declineOutperformRX wrote: Calvinsin. I totally agree that they should hire more people to answer investor questions. They are doubling sales force for Donnatal in US and it is obvious the feeling among the conference participants is that the scope of the AMCo portfolion in the US is being questioned as well as increased scrutiny to take price in Europe, also a question at the conference. I asked IR why they are increasing Donnatol sales force so much and they haven't answered my question either. So I asked my doctor. She said Donnatal is being quickly displaced by H2 antagonists as in slinical rials it is showing more effectiveness and lack many of the advserse effects of phenobarbital. Pumpers, plese report to your laptops. Not sure if she is correct or not but there has to be a reason why they are pushing the Donnatal cocktail.
Donnatal (wikipedia): "
Recent clinical trials showed that Donnatal was no more effective than plain antacid in relieving the symptoms of dyspepsia.[1][2] However, the active ingredients in Donnatal® have been shown to be more effective than placebo in treating moderately severe symptoms of irritable bowel syndrome.[3] It is also a common component of a GI cocktail used in emergency rooms. In 1976, Donnatal was one of the 25 most widely prescribed drugs in the U.S.[4] It has since been displaced by H2 antagonists and proton pump inhibitors, which are more effective and lack many of the adverse effects of phenobarbital.[5]"